Investment Rating - The report assigns a "Buy" rating for JD Health (06618) for the first time [2]. Core Insights - JD Health aims to build a comprehensive health management platform centered on pharmaceutical and health product supply, leveraging its supply chain and logistics capabilities to become the largest pharmaceutical retail channel in China [8]. - The opening of online medical insurance purchasing rights is seen as a significant short-term catalyst for the industry, with expectations of increased online drug sales due to policy support [8]. - The company is expected to benefit from the increasing online penetration of pharmaceutical products and the opening of online medical insurance payment permissions, with projected revenues of 70.9 billion, 82.4 billion, and 94.2 billion RMB for 2025-2027 [8]. Summary by Sections Company Overview - JD Health, established in 2018, is a subsidiary of JD Group focused on healthcare, aiming to create a digital-driven health management platform covering the entire lifecycle of users [11]. - The company has a strong market position, with over 15,000 partnered pharmacies and a presence in more than 490 cities across China [11][29]. Pharmaceutical E-commerce Business - The report highlights the importance of the opening of online medical insurance purchasing rights and the increasing online penetration of pharmaceutical sales as key growth drivers [23]. - JD Health's strategy includes a combination of self-operated, platform-based, and instant retail channels to enhance service capabilities and meet urgent medication needs [26][29]. Financial Forecasts and Valuation - Revenue projections for JD Health are set at 70.9 billion, 82.4 billion, and 94.2 billion RMB for 2025, 2026, and 2027, respectively, with adjusted net profits expected to be 5.7 billion, 6.2 billion, and 7.2 billion RMB [34]. - The report anticipates a gradual improvement in gross margins and a decrease in marketing expenses over time, reflecting operational efficiencies [34]. Management and Shareholder Structure - The management team is experienced, with a stable ownership structure, where JD Jiankang Limited holds 67.16% of the shares, controlled by Liu Qiangdong [13][15].

Investment Rating - The report assigns a "Buy" rating to China Pacific Insurance (2328) with a target price of HKD 23.30, representing a 21.7% upside from the current price of HKD 18.62 [2][10]. Core Insights - The company is undergoing a structural transformation in its non-auto insurance business and is expanding internationally, which is expected to drive a second growth curve [5][8]. - In the first three quarters of 2025, the company achieved insurance service revenue of CNY 385.9 billion, a year-on-year increase of 5.9%, with net profit rising by 50.5% to CNY 40.3 billion [5]. - The non-auto insurance segment has become a core growth engine, with original premium income reaching CNY 223.06 billion, accounting for 50.3% of total premiums [6]. Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported total investment income of CNY 35.9 billion, a 33% increase year-on-year, with an annualized total investment return rate of 5.4%, up by 0.8 percentage points [5]. - The projected earnings per share (EPS) for 2025 is HKD 2.575, reflecting a 14% increase from the previous estimate [2]. Non-Auto Insurance Business - The report highlights that the non-auto insurance business is expected to benefit from new regulatory policies aimed at improving profitability and cost efficiency [6]. - The company aims to maintain a combined cost ratio of less than 96% for auto insurance and 99% for non-auto insurance in 2025 [6]. International Expansion - The international strategy is designed to significantly increase overseas business within five years, focusing on supporting Chinese enterprises' global expansion, particularly in the new energy vehicle sector [7]. - The company has already established operations in Hong Kong and Thailand, with plans to expand into Europe and Southeast Asia [7]. Future Projections - The report forecasts net profits for 2025, 2026, and 2027 to be CNY 51.5 billion, CNY 54.3 billion, and CNY 59.1 billion, respectively, indicating a growth trajectory of 60%, 5%, and 9% [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating expected returns exceeding the market benchmark by more than 15% over the next 6-12 months [4]. Core Insights - The company reported a revenue of $1.324 billion in Q3 2025, representing a year-on-year increase of 13%, and a net profit of $74 million, up 9% year-on-year, with a net profit margin of 5.62% [1]. - The growth in revenue is attributed to increased contributions from AI server-related products, ongoing production efficiency improvements, and stable shipments of high-margin products [1]. - The data center and electric vehicle (EV) businesses experienced significant revenue growth, while smartphone revenue declined [1][2]. Summary by Sections Revenue and Profit Performance - In Q3 2025, revenue from various segments was as follows: smartphones $210 million (down 20%), data centers $215 million (up 34%), computers and consumer electronics $221 million (no change), electric vehicles $240 million (up 116%), and system terminal products $382 million (up 3%) [1][3]. - The company has raised its revenue growth guidance for system terminal products for Q4 2025, while maintaining the overall revenue growth guidance for the year [1]. Business Segments - The data center business is expected to maintain double-digit growth (over 15% year-on-year) in Q4 2025 and for the full year, driven by increased demand for AI server products [2]. - The automotive business saw a 116% year-on-year increase in revenue, supported by the One Mobility strategy and rising demand for data connectivity and high-power solutions [3]. - The system terminal products segment is projected to have stable revenue in Q4 2025, with a slight decline expected for the full year [3]. Financial Forecasts and Valuation - The net profit forecast for 2025 is $171 million, with subsequent years projected at $297 million for 2026 and $400 million for 2027, reflecting growth rates of 11.4% and 73.7% respectively [5]. - The company’s price-to-earnings (P/E) ratios are projected to be 29x for 2025, 17x for 2026, and 12x for 2027, indicating a favorable valuation outlook [4].

Investment Rating - The report assigns a "Buy" rating to the company, indicating a potential upside of 15% to less than 35% [6][9]. Core Insights - The company reported a total revenue of 27.595 billion yuan for Q3, a year-on-year increase of 44.2%, with product revenue contributing 27.31 billion yuan, up 43.9% year-on-year. The net profit attributable to shareholders was 1.139 billion yuan, significantly improving from a net loss of 3.687 billion yuan in the same period last year [6]. - The strong growth in revenue is primarily driven by the sales of the self-developed product, Zebutinib, which achieved global sales of 7.4 billion yuan in Q3, marking a 51% year-on-year increase [6]. - The company has adjusted its revenue guidance upwards, now forecasting revenue between 36.2 billion and 38.1 billion yuan for the year, while also slightly lowering the upper limit of its R&D and operating expenses forecast [6]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a current H-share price of 197.40 HKD and a market capitalization of 171.823 billion yuan [2]. Financial Performance - For Q3, the company achieved a revenue of 10.08 billion yuan, a 41.1% increase year-on-year, with a net profit of 690 million yuan, recovering from a loss of 810 million yuan in the previous year [6]. - The company expects net profits to turn positive in 2025, with projections of 1.97 billion yuan, followed by 3.92 billion yuan in 2026 and 6.42 billion yuan in 2027 [8]. Product Pipeline - The company is advancing several products in its pipeline, including Sotoclisib, which has received breakthrough therapy designation from the FDA, and other products in various stages of clinical trials [6]. Valuation Metrics - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.94 yuan, 3.86 yuan, and 6.32 yuan, respectively, with corresponding H-share price-to-earnings (P/E) ratios of 93, 47, and 29 [8].

Investment Rating - The report maintains a "Buy" rating for the company [5][12]. Core Views - The company is expected to see steady growth in its retail segment, with a projected revenue of 2,486.7 billion yuan for Q3 2025, reflecting a year-over-year increase of 10.5% [8]. - The report anticipates a narrowing of losses in the food delivery segment due to strategic reductions in subsidies and improved operational efficiency [8]. - The target price for the company's stock is set at 190.96 HKD, based on a valuation of 9X PE for retail and new businesses in 2026 [12]. Financial Forecasts - Revenue projections for 2025-2027 are adjusted to 13,312 billion, 14,094 billion, and 14,856 billion yuan, respectively, with net profits expected to be 271 billion, 438 billion, and 525 billion yuan [3][12]. - The company is expected to achieve a gross margin of 15.8% in 2025, with a net profit margin of 1.55% [10]. - The operating profit margin (OPM) for Q3 2025 is projected to be 5.5%, indicating a year-over-year increase of 0.34% [8]. Segment Performance - The retail segment is projected to achieve a revenue of 1,155,005 million yuan in 2025, with a year-over-year growth rate of 14.87% [10]. - The logistics segment is expected to generate revenue of 493.0 billion yuan in Q3 2025, reflecting a year-over-year increase of 11.1% [8]. - New business revenue is forecasted to reach 128.7 billion yuan in Q3 2025, with a significant year-over-year growth of 158.9% [8].

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of HKD 49.09, indicating an expectation of over 20% outperformance against the benchmark index in the next six months [2][24]. Core Insights - The company is accelerating its global business expansion, having added four new branches through strategic acquisitions domestically and formed a partnership with Singapore's digital healthcare platform 1doc for overseas growth [2]. - The management's confidence in the company's future is demonstrated through a significant share buyback program, which has seen a total repurchase of 8.14 million shares for approximately HKD 247 million [2][8]. Financial Performance Summary - Total revenue is projected to grow from HKD 3,022 million in 2024 to HKD 4,845 million by 2027, reflecting a compound annual growth rate (CAGR) of approximately 20.1% [4]. - Net profit attributable to shareholders is expected to increase from HKD 307 million in 2024 to HKD 664 million in 2027, with a notable growth rate of 30.5% in 2025 [4]. - Earnings per share (EPS) is forecasted to rise from HKD 1.26 in 2024 to HKD 2.87 in 2027, indicating strong profitability growth [4]. Strategic Developments - The company has successfully entered key cities such as Tianjin, Chengdu, and Shantou, enhancing its regional service capabilities through strategic acquisitions [8]. - The partnership with 1doc aims to leverage existing healthcare networks in Singapore, facilitating the company's international expansion and patient conversion in integrated Chinese and Western medicine settings [8]. Share Buyback Program - Since initiating the buyback plan on September 1, 2025, the company has conducted 42 repurchase transactions, with a total buyback volume of 8.14 million shares and a total investment of approximately HKD 247 million [8]. - The board has approved an additional buyback authorization of up to HKD 300 million, bringing the total buyback scale to a record HKD 600 million since the company's listing [8].

Investment Rating - The report maintains a "Buy" rating for the company [6] Core Insights - Merck has entered into a $700 million collaboration with Blackstone Life Sciences to accelerate the global development of sacituzumab tirumotecan (sac-TMT) [1][2] - The funding will support part of the R&D costs for sac-TMT in 2026, with Blackstone entitled to a low to mid-single-digit royalty on net sales of sac-TMT in approved indications [2] - Merck is actively advancing sac-TMT's clinical development, with 15 global Phase III trials ongoing for six types of tumors, including lung cancer and breast cancer [3] Financial Projections - Projected revenues for the company are expected to be CNY 2.084 billion, CNY 2.876 billion, and CNY 4.663 billion for the years 2025, 2026, and 2027 respectively, with net profits of CNY -622 million, CNY -130 million, and CNY 561 million [6]

Investment Rating - The investment rating for Geely Automobile is "Buy" and is maintained [6]. Core Insights - Geely Automobile reported a total sales volume of 307,000 units in October 2025, representing a year-on-year increase of 35.5% and a month-on-month increase of 12.5% [2][4]. - Cumulative sales from January to October 2025 reached 2.477 million units, up 44.3% year-on-year [2][4]. - The company is expected to enter a new product era supported by the GEA architecture, with positive developments across its brands including Zeekr, Lynk & Co, and Galaxy [7]. - The transition to new energy vehicles is progressing smoothly, with scale effects expected to enhance profitability [7]. - Geely's strong foundation in fuel vehicles and innovative overseas expansion strategies are opening new markets [7]. - The company is set to launch 10 new energy models in 2025, with significant advancements in smart driving capabilities [7]. Summary by Sections Sales Performance - October 2025 sales reached 307,000 units, with Geely brand, Lynk & Co, and Zeekr sales at 245,000, 40,000, and 21,000 units respectively [7]. - Galaxy brand achieved 127,000 units in October, marking a 100.8% increase year-on-year [7]. - Exports in October totaled 42,000 units, up 22.6% year-on-year [7]. - New energy vehicle sales in October were 178,000 units, accounting for 57.9% of total sales, a year-on-year increase of 63.6% [7]. Product Strategy - Geely plans to launch 10 new energy models in 2025, including five new models and several facelifts [7]. - The company is enhancing its smart driving capabilities, with new models expected to feature advanced driving technologies [7]. Financial Outlook - The projected net profit for 2025 is 16.1 billion yuan, with a corresponding price-to-earnings ratio of 10.6X [7].

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Insights - In October 2025, the company delivered 42,013 new vehicles, representing a year-on-year increase of 75.7% and a month-on-month increase of 1.0% [2][4]. - Cumulatively, from January to October 2025, the company delivered 355,000 new vehicles, marking a year-on-year increase of 190.0% [2][4]. - The company is expected to see steady sales growth driven by strong new vehicle cycles, enhanced marketing systems, and ongoing improvements in smart driving technology [2][9]. - The new models MONA M03 and P7+ are expected to initiate a new vehicle cycle for the company [9]. Summary by Sections Sales Performance - October 2025 saw a record monthly delivery of over 40,000 vehicles, with significant contributions from the new P7 model and strong sales of the SUV family [9]. - The MONA M03 model alone delivered over 15,000 units in October, with total deliveries exceeding 200,000 since its launch [9]. Future Outlook - For Q3 2025, the company anticipates deliveries between 113,000 and 118,000 units, representing a year-on-year growth of 142.8% to 153.6% [9]. - Expected revenue for Q3 2025 is projected to be between 19.6 billion and 21 billion CNY, reflecting a year-on-year increase of 94.0% to 107.9% [9]. Strategic Developments - The company is expanding its international presence, having entered seven new markets in Europe, Asia, and Africa, transitioning from rapid expansion to solid operations [9]. - The upcoming launch of the next-generation extended-range product, the X9, is anticipated to enhance the company's competitive edge with its unique features [9].

Investment Rating - The report maintains a "Buy" rating for Hong Kong Exchanges and Clearing Limited (00388.HK) [2][9] Core Views - The report indicates that the Hong Kong stock market's liquidity is expected to continue to rise due to a series of connectivity policies, leading to increased market activity and valuation [2][6] - For the years 2025-2027, the company is projected to achieve revenues and other income of HKD 282.86 billion, HKD 304.18 billion, and HKD 322.14 billion, respectively, with net profit attributable to shareholders of HKD 173.74 billion, HKD 188.57 billion, and HKD 200.92 billion, corresponding to PE ratios of 30.91, 28.48, and 26.73 times [2][6] Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenues and other income of HKD 218.51 billion, a year-on-year increase of 36.63%, and a net profit attributable to shareholders of HKD 134.19 billion, up 44.8% year-on-year [6][9] - Revenue growth was driven by significant increases in trading and transaction fees, listing fees, and settlement and clearing fees, with respective year-on-year growth rates of 57.28%, 17.08%, and 65.66% [6][9] Market Activity - The report highlights a substantial increase in trading activity across the cash, derivatives, and commodities markets, with daily average trading volumes for cash securities up 132.4% year-on-year [6][9] - The report notes that the number of new listings and the amount raised in the first three quarters of 2025 saw significant growth, with new listings totaling 69 and fundraising amounts increasing by 258.5% [6][9] Investment Income - Investment income for Q3 2025 was reported at HKD 10.18 billion, reflecting a quarter-on-quarter decline of 16% and a year-on-year decrease of 34% [6][9] - The annualized investment return rate for margin and clearing house fund investments decreased by 0.15 percentage points to 1.46% [6][9] Future Projections - The report anticipates continued growth in revenues and profits for the company, driven by favorable market conditions and policy support, with projected revenues of HKD 282.86 billion in 2025, HKD 304.18 billion in 2026, and HKD 322.14 billion in 2027 [2][10]